Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)

188
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Swiss Exchange
10/20/2014 10/21/2014 10/22/2014 10/23/2014 10/24/2014 Date
268.6(c) 274.7(c) 278.3(c) 279.4(c) 278(c) Last
1 449 233 2 376 159 1 533 508 1 314 581 1 166 433 Volume
+0.34% +2.27% +1.31% +0.40% -0.50% Change
More quotes
Company
Roche Holding AG is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics.As a large biotech company, Roche has truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.It is also a leader in in-vitro... 
Sector
Pharmaceuticals
Calendar
11/11Presentation
Surperformance© rating of Roche Holding Ltd.
Trading Rating : Investor Rating :
More about the company
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Full-screen chart
Financials ( CHF)
Sales 2014 47 200 M
EBIT 2014 17 545 M
Net income 2014 11 815 M
Debt 2014 6 201 M
Yield 2014 2,96%
Sales 2015 49 541 M
EBIT 2015 18 814 M
Net income 2015 12 871 M
Finance 2015 889 M
Yield 2015 3,19%
PER 2014 20,00
PER 2015 18,21
EV / Sales 2014 5,18x
EV / Sales 2015 4,79x
Capitalization 238 432 M
More Financials
Latest news on ROCHE HOLDING LTD.
3d ago Roche to spend $3.2 billion on towering Basel base
3d agoDJRoche to Spend CHF3 Billion in Research Center, Basel Headquarters
10/16 ROCHE : Pharmacyclics Enters Into Agreement with Roche to Evaluate IMBRUVICA® an..
10/16 New breast cancer drugs boost sales at Roche
10/15 ROCHE : FDA Approves Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulm..
10/13DJRoche Holding 3Q 2014 -- Forecast
10/08 ROCHE : FDA Grants Priority Review for Genentech’s Lucentis in Diabetic Re..
10/08 NOVARTIS : Shareholder group critical as Roche and Novartis chiefs top Swiss pay..
09/29 ROCHE : Genentech :’s Investigational Combination of Cobimetinib Plus Zelb..
09/28 ROCHE : Genentech :’s Perjeta Regimen Extended the Lives of People With an..
09/24 Adaptimmune raises $104 million to develop immune-system cancer drugs
09/17 For Roche CEO, celebrating failure is key to success
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF